Loading stock data…
Trevi Therapeutics, Inc. (TRVI)
$16.82-0.44 (-2.55%)
Market ClosedLast close Sep 8
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Trevi Therapeutics, Inc. in the Healthcare sector is trading at $16.82 with a market capitalization of $2.4B. Wall Street consensus targets $28.18 (11 analysts), implying a +67.5% move over the next 12 months. The stock is currently 17% below its 52-week high of $20.22, remaining 19.6% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. Risk note: RSI 23 is oversold, raising the odds of a near-term bounce. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +67.5% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Oversold momentum (RSI 23) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$20.51M↓ | -$14.91M↓ | -$10.22M↑ | -$13.92M↓ | -$13.72M |
| Net Income | -$17.80M↓ | -$13.19M↓ | -$8.32M↑ | -$11.80M↑ | -$12.30M |
Peer Comparison
JNJUNHPFE
Fundamentals
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, a...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.40B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.05
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-15.90%
Volume
Today's trading volume
1.48M
Recent News
Trevi Therapeutics (TRVI) Stock Trades At A Premium To Fair Value
Trevi Therapeutics has delivered very strong long term gains, yet the stock now screens as expensive on broad valuation checks. This raises questions about how much of the story is already in the price. The stock has returned roughly 10x over the past 5 years, which is an unusually large move that can leave less room for valuation mistakes. Upcoming presentations in 2026 on nalbuphine ER trial data may support confidence in the Trevi Therapeutics pipeline. Any disappointment in clinical...
Trevi Therapeutics Q2 Earnings Call Highlights
Trevi Therapeutics (NASDAQ:TRVI) said it began two clinical trials during the second quarter and plans to launch a third study in the third quarter as it advances nalbuphine ER, also known as Haduvio, for multiple chronic-cough indications. President and Chief Executive Officer Jennifer Good said t
Trevi Therapeutics Inc (TRVI) (Q2 2026) Earnings Call Highlights: Advancing Phase 3 Pipeline ...
Trevi Therapeutics Inc (TRVI) reports progress in IPF and RCC trials, backed by $319 million in funding and a competitive edge following a rival's program exit.
Trevi Therapeutics (TRVI) Soars as Haduvio Taps Into $15B Addressable Market
Trevi Therapeutics grew its share prices by 9.85 percent on Friday to finish at $19.07 apiece, after management underscored strong clinical trial results from its treatment candidate for chronic cough. Speaking at a three-day conference in Europe, Trevi Therapeutics Inc (NASDAQ:TRVI) CEO Jennifer Good and Chief Development Officer James Cassella highlighted that the oral treatment […]
Trevi Therapeutics Is Up 100%, Pivotal bioVenture Adds Anyway. Here's Why That Matters.
This clinical-stage biotech targets chronic pruritus and cough with its lead therapy for neurologically mediated diseases.